Citadel Advisors
INZY

Citadel Advisors’s Inozyme Pharma INZY Stock Holding History

Citadel Advisors’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,000
Closed -$910 – 13756
2025
Q1 		$910 Sell
1,000
-4,100
-80% -$5.68K ﹤0.01% 14199
2024
Q4 		$14.1K Sell
5,100
-700
-12% -$2.66K ﹤0.01% 13418
2024
Q3 		$30.3K Buy
5,800
+3,100
+115% +$16.1K ﹤0.01% 12426
2024
Q2 		$12K Sell
2,700
-3,200
-54% -$15.5K ﹤0.01% 13001
2024
Q1 		$45.2K Sell
5,900
-4,900
-45% -$26.9K ﹤0.01% 12258
2023
Q4 		$46K Buy
10,800
+1,000
+10% +$3.55K ﹤0.01% 11858
2023
Q3 		$41.2K Sell
9,800
-11,300
-54% -$57.5K ﹤0.01% 11970
2023
Q2 		$118K Sell
21,100
-1,700
-7% -$10K ﹤0.01% 10688
2023
Q1 		$131K Buy
+22,800
New +$60.2K ﹤0.01% 10858

Citadel Advisors's INZY Position: Q3 2025 in Review

Citadel Advisors sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 35,166 shares — an estimated $141K sold.

Citadel Advisors first reported a position in INZY in Q3 2020 and held it in 19 quarters. The position peaked at $6.34M in Q3 2020. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.

  • Citadel Advisors reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 35,166 Inozyme Pharma shares in Q3 2025, an estimated $141K.
  • Citadel Advisors first reported a position in Inozyme Pharma in Q3 2020 and held it in 19 quarters.
  • Citadel Advisors's Inozyme Pharma position peaked at $6.34M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.